| [ Summary ] |
Nucleotide/nucleoside analog (NA) is one of the most effective treatments for HBV infection. It inhibits DNA polymerase and suppresses the replication of HBV. Adverse effects of NAs are mild compared with those of IFN therapy. NA therapy can achieve HBV DNA negative conversion and normalize alanine aminotransferase (ALT) level at a high rate. Indication for NA treatment is based on ALT level, HBV DNA level, and presence of cirrhosis. The aims of the treatment are ALT normalization, sustained HBV DNA negative rates, and loss of HBs antigen. These contribute to suppression of liver carcinogenesis, fibrosis, and liver‒related death. Currently, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide Fumarate (TAF) are recommended as first line NAs. --Understanding the characteristics and adverse effects of these three agents would contribute to good medical practice. |